Life Science / Inhibitors/Agonists / Epigenetics / Epigenetic Reader Domain / SGC-CBP30

SGC-CBP30

Cat No.: A636668 Purity: 98% For Research Use Only.

Chemical Structure of SGC-CBP30 CAS No.:1613695-14-9 Chemical Structure of SGC-CBP30
CAS No.:1613695-14-9
3D Chemical Structure of SGC-CBP30
CAS No.:1613695-14-9
Chemical Structure of SGC-CBP30 CAS No.:1613695-14-9
3D Chemical Structure of SGC-CBP30 CAS No.:1613695-14-9
Size USA Stock *0-1 Day Global Stock *5-7 Days Price VIP Price Quantity
{[ item.pr_size ]} {[ item.pr_usastock ]} Inquiry - {[ item.pr_chinastock ]} Inquiry -

{[ getRatePrice(item.pr_usd, 1,1) ]}

{[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]}
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} - +
Cart0 Add to My Favorites

QC Information of SGC-CBP30

Cat No.: A636668 Purity: 98% Batch: Standard Purity:
Name/Description BET bromodomain BRPF CBP/beta-catenin p300/CBP Other Targets Purity
MS436 ++

BRD4 (2), Ki: 0.34 μM

BRD4 (1), Ki: <0.085 μM

99%+
CPI-203 +++

BRD4, IC50: 37 nM

99+%
GSK1324726A +++

BRD2, IC50: 31 nM

BRD4, IC50: 22 nM

99%+
PFI-1 ++

BRD2, IC50: 98 nM

BRD4, IC50: 0.22 μM

99%+
Apabetalone +

BD2, IC50: 0.51 μM

99%
(+)-JQ1 +++

BRD4 (2), IC50: 33 nM

BRD4 (1), IC50: 77 nM

98%
I-BET151 +

BRD3, IC50: 0.25 μM

BRD4, IC50: 0.5 μM

99%+
Molibresib +++

BET proteins, IC50: 35 nM

99%+
I-BRD9 +++

BRD4, pIC50: 5.3

BRD9, pIC50: 7.3

99%+
BI-7273 ++++

BRD7, IC50: 117 nM

BRD9, IC50: 19 nM

99+%
Pelabresib +++

BRD4-BD1, IC50: 39 nM

98%
ARV-825 +++

BRD4 BD2, Kd: 28 nM

BRD4 BD1, Kd: 90 nM

99%+
Birabresib 99%+
BI 2536 +++

BRD4, Kd: 37 nM

c-Myc 99%+
Bromosporine ++

BRD2, IC50: 0.29 μM

BRD9, IC50: 0.122 μM

++++

CECR2, IC50: 17 nM

99%+
XMD8-92 ++

BRD4 (1), Kd: 170 nM

99%+
Mivebresib 99%+
BI-9564 ++++

BRD9, Kd: 5.9 nM

BRD7, Kd: 73 nM

++

CECR2, Kd: 77 nM

99%+
AZD5153 6-Hydroxy-2-naphthoic acid ++++

FL-BRD4, IC50: 5 nM

99%+
PLX51107 ++++

BRD4 BD2, Kd: 1.7 nM

BRD3 BD1, Kd: 2.1 nM

99%+
FL-411 +

BRD4(1), IC50: 0.43 μM

98%+
ABBV-744 99%+
dBET6 ++++

BRD4, IC50: 14 nM

99%+
dBET1 ++++

BRD4, IC50: 20 nM

99%+
MZ1 ++++

Brd3(BD2), Kd: 13 nM

Brd2(BD2), Kd: 62 nM

99%+
dBET57 +

BRD4BD1, DC50: 500 nM

99%+
SF2523 +

BRD4, IC50: 241 nM

DNA-PK 99%+
INCB054329 ++++

BRD4-BD1, IC50: 119 nM

BRD3-BD1, IC50: 9 nM

99%
INCB-057643 99%+
(E/Z)-ZL0420 +++

BRD4 BD1, IC50: 27 nM

BRD4 BD2, IC50: 32 nM

99%+
BMS-986158 99%+
BRD4 Inhibitor-10 ++++

BRD4-BD1, IC50: 5 nM

BRD4-BD2, IC50: 41 nM

97%
A1874 99%+
Y06036 ++

BRD4 (1), Kd: 82 nM

99%+
Alobresib NF-κB 98%
ODM-207
GSK778 +++

BRD4-BD1, IC50: 143 nM

BRD2-BD1, IC50: 75nM

97%
SRX3207 +

BRD42, IC50: 3070 nM

BRD41, IC50: 3070 nM

Syk 98%
GSK046 +++

BRD4BD2, IC50: 214 nM

BRD3BD2, IC50: 98 nM

98%
GSK620 97%
Thalidomide-NH-C4-NH-Boc 98%
Trotabresib 99%
NHWD-870 98%
CFT8634 ++++

BRD9, DC50: 3 nM

98%
GSK2801 ++

BAZ2B, Kd: 136 nM

BAZ2A, Kd: 257 nM

99%+
KG-501 99%+
UNC 669 +

L3MBTL3, IC50: 35 μM

L3MBTL4, IC50: 6 μM

98%
PFI-3 +++

SMARCA4, Kd: 55 nM

SMARCA2A, Kd: 72 nM

99%+
UNC1215 +++

L3MBTL3, IC50: 120 nM

L3MBTL3- D274A, IC50: 3.5 μM

99%+
EED226 ++

PRC2, Kd: 114 nM

EED, Kd: 82 nM

99%+
BRD9539 99%+
UNC926 +

L3MBTL1, Kd: 3.9 μM

99%
666-15 ++

CREB, IC50: 81 nM

99%+
UNC6852 +

EED, IC50: 247 nM

99%+
BAZ1A-IN-1 +

BAZ1A, Kd: 0.52 μM

99%+
PFI-4 ++

BRPF1, IC50: 80 nM

BRPF2, IC50: 7.9 μM

99%+
OF-1 ++

BRPF2, Kd: 500 nM

BRPF1B, Kd: 100 nM

99%+
GSK-5959 ++

BRPF3, pIC50: 7.1

BRPF2, pIC50: 5.2

99+%
GSK6853 ++++

BRPF1, pIC50: 8.1

99%+
NI-42 ++++

BRPF1, IC50: 48 nM

BRPF3, IC50: 260 nM

99%+
E-7386 +++

CBP/beta-catenin, IC50: 0.0484 μM

97%
I-CBP112 ++

CBP, Kd: 151 nM

p300, Kd: 167 nM

98+%
Histone Acetyltransferase Inhibitor II +

p300, IC50: 5 μM

99%+
C646 +

p300/CBP, Ki: 400 nM

99%+
Anacardic Acid +

p300/CBP, IC50: 8.5 μM

PCAF, IC50: 5 μM

99%+
SGC-CBP30 ++++

CREBBP, IC50: 21 nM

EP300, IC50: 38 nM

99%+
Nordihydroguaiaretic acid IGF-1R,HER2 99%+
Curcumin +

p300, IC50: ~25 μM

Nrf2,NF-κB,Ferroptosis 98%
CPI-637 +++

CBP, IC50: 0.03 μM

EP300, IC50: 0.051 μM

99%+
Foscenvivint β-catenin 99%+
A-485 ++

p300 HAT, IC50: 0.06 μM

99%+
GNE-781 +

BRD4(1), IC50: 5100 nM

++++

CBP, IC50: 0.94 nM

98+%
NEO2734 +++

BET, IC50: <30 nM

+++

p300/CBP, IC50: <30 nM

99%+
1. Hovering the mouse over the "+" can display the specific value of the relevant IC50. The more "+", the stronger the inhibitory effect. 2. "✔" Indicates that the compound has inhibitory effects on the corresponding subtypes, but there is currently no relevant data on the intensity of inhibition.

Biological Activity of SGC-CBP30

Targets
  • p300/CBP

    CREBBP, IC50:21 nM

    EP300, IC50:38 nM

Protocol of SGC-CBP30

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

1.96mL

0.39mL

0.20mL

9.82mL

1.96mL

0.98mL

19.64mL

3.93mL

1.96mL

Technical Information of SGC-CBP30

CAS No.1613695-14-9
FormulaC28H33ClN4O3
M.W.509.04
Solubility
Storage
  • Powder
  • |
  • In solvent -20°C:3 months-80°C:12 months
ShippingBlue ice
Synonyms
Formulation